362 related articles for article (PubMed ID: 11491419)
21. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
[TBL] [Abstract][Full Text] [Related]
22. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
[TBL] [Abstract][Full Text] [Related]
23. Update on nevirapine: quest for a niche.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1997 Sep; 3(9):37-43. PubMed ID: 11364713
[TBL] [Abstract][Full Text] [Related]
24. Reverse transcriptase fidelity and HIV-1 variation.
Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
[No Abstract] [Full Text] [Related]
25. Primary lamivudine resistance in acute/early human immunodeficiency virus infection.
Conway B; Montessori V; Rouleau D; Montaner JS; O'Shaughnessy MV; Fransen S; Shillington A; Weislow O; Mayers DL
Clin Infect Dis; 1999 Apr; 28(4):910-1. PubMed ID: 10825060
[No Abstract] [Full Text] [Related]
26. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
Casado JL; Hertogs K; Ruiz L; Dronda F; Van Cauwenberge A; Arnó A; Garcia-Arata I; Bloor S; Bonjoch A; Blazquez J; Clotet B; Larder B
AIDS; 2000 Jan; 14(2):F1-7. PubMed ID: 10708276
[TBL] [Abstract][Full Text] [Related]
27. Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.
Winters MA; Kagan RM; Kovari L; Heseltine PN; Merigan TC
Antivir Ther; 2005; 10(2):363-6. PubMed ID: 15865232
[TBL] [Abstract][Full Text] [Related]
28. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
Lori F; Lisziewicz J
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
[TBL] [Abstract][Full Text] [Related]
29. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.
Taylor S; Reynolds H; Sabin CA; Drake SM; White DJ; Back DJ; Pillay D
AIDS; 2001 Oct; 15(15):2051-3. PubMed ID: 11600838
[TBL] [Abstract][Full Text] [Related]
30. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
[TBL] [Abstract][Full Text] [Related]
31. Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
La Regina G; Coluccia A; Brancale A; Piscitelli F; Gatti V; Maga G; Samuele A; Pannecouque C; Schols D; Balzarini J; Novellino E; Silvestri R
J Med Chem; 2011 Mar; 54(6):1587-98. PubMed ID: 21366296
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
[TBL] [Abstract][Full Text] [Related]
33. Current insights into reverse transcriptase inhibitor-associated resistance.
Wainberg MA; White AJ
Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
[No Abstract] [Full Text] [Related]
34. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
[No Abstract] [Full Text] [Related]
35. Can early failure with nevirapine be rescued with efavirenz?
Briones C; Soriano V; Dona C; Barreiro P; González-Lahoz J
J Acquir Immune Defic Syndr; 2000 May; 24(1):76-8. PubMed ID: 10877499
[No Abstract] [Full Text] [Related]
36. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
[TBL] [Abstract][Full Text] [Related]
37. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation.
Tachedjian G; Moore KL; Goff SP; Sluis-Cremer N
FEBS Lett; 2005 Jan; 579(2):379-84. PubMed ID: 15642347
[TBL] [Abstract][Full Text] [Related]
38. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir.
Van Laethem K; Witvrouw M; Balzarini J; Schmit JC; Sprecher S; Hermans P; Leal M; Harrer T; Ruiz L; Clotet B; Van Ranst M; Desmyter J; De Clercq E; Vandamme AM
AIDS; 2000 Mar; 14(4):469-71. PubMed ID: 10770556
[No Abstract] [Full Text] [Related]
39. Clinical utility of resistance testing.
Stebbing J; Gazzard BG
J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
[No Abstract] [Full Text] [Related]
40. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
